Introduction
BCR/ABL oncogenic tyrosine kinase exhibits two complementary roles in cancer. The first, and bestknown is stimulation of signaling pathways that render cells independent of their environment. BCR/ABL allows cells to proliferate in the absence of growth factors, protects them from apoptosis in the absence of external survival factors, and promotes invasion and metastasis (Sawyers, 1997) . The second role of BCR/ ABL in hematological malignancies, which is only just beginning to be fully recognized, is that it can render cells resistant to genotoxic therapies (AmaranteMendes et al., 1998b; Bedi et al., 1995; Dubrez et al., 1998; Nishii et al., 1996; Slupianek et al., 2001) . Treatment of chronic myelogenous leukemia (CML) with chemotherapy leads to a transient reduction of the number of leukemic cells (Fischer et al., 1998) . However, the leukemic cells usually recover more quickly than normal hematopoiesis. Therefore, these therapies do not mediate durable remissions in CML patients. In addition, high-dose chemotherapy treatment combined with stem cell transplantation does not eradicate the disease in most patients as indicated by the poor efficacy of syngeneic twin transplantation in CML (Gale et al., 1994) . This clinical data shows that BCR/ABL-positive hematopoietic cells are resistant to apoptosis induced by chemotherapeutic agents. Although still disputed (Albrecht et al., 1996; Amos et al., 1995; Deutsch et al., 2001; Santucci et al., 1993) , a growing body of evidence suggests that BCR/ABL can also protect cells from g-radiation Fuchs et al., 1995; Jeong et al., 2001; Nishii et al., 1996; Papazisis et al., 2000; Riordan et al., 1998; van der Kuip et al., 2001) .
Usually the mechanisms of resistance to therapeutic agents do not seem to be a direct consequence of malignant transformation, but rather arise as a result of selection of tumor cell clones that can develop protective mechanisms diminishing DNA damage due to enhanced drug metabolism and/or efflux (el-Deiry, 1997; Harrison, 1995; Pegram et al., 1997) . By contrast, cells transformed by BCR/ABL, when compared with normal cells, may have a tendency to accumulate more DNA damage as measured by comet assays (Slupianek et al., 2002) . The mechanism of this effect is not known, but we hypothesize that some of the DNA damage might represent intermediates in an accelerated process of repair (double-strand breaks occur when replication forks encounter DNA lesions (Michel et al., 2001) ), and/ or there might be an additive effect of DNA damage induced by genotoxic agents and that induced by production of reactive oxygen species (ROS) in BCR/ ABL-transformed cells .
Malignancies induced by BCR/ABL may display early drug resistance at CML chronic phase stage , excluding the clonal selection favoring overexpression of mdr-1, altered doubling time or cell cycle repartition (Dubrez et al., 1995) . On the other hand, early pre-B leukemia cells from p190-BCR/ABL transgenic mice did not demonstrate resistance to g-radiation . In addition, experiments on growth factor-dependent cell lines indicated that BCR/ABL mediated protection from DNA damage-induced apoptosis in a dose-dependent manner (Cambier et al., 1998) . Since the expression of BCR/ ABL at the chronic phase is usually low, but increases at the accelerated phase and blast crisis (Gaiger et al., 1995) , it seems reasonable to speculate that at the initial phase of the disease relatively low levels of BCR/ ABL may stimulate only moderate resistance to DNA damage-induced apoptosis, whereas at the later stages high levels of BCR/ABL trigger more pronounced resistance. Thus, if selection is involved in development of resistance to DNA damage-induced apoptosis in BCR/ABL cells, it is associated with the emergence of clones overexpressing the oncogene rather than the modification of drug metabolism and/or uptake/efflux. However, as the CML progresses, cells can accumulate additional genetic abnormalities such as: mutations/ deletions of p53 (Beck et al., 2000; Guinn et al., 1995; Nakai et al., 1992; Stuppia et al., 1997) , which further increase the resistance of these cells to genotoxic treatment (Makin and Hickman, 2000) , but this effect is not dependent on the BCR/ABL catalytic activity.
Resistance to DNA damage-dependent apoptosis
If detoxification, inactivation and efflux are not important mechanisms of BCR/ABL-induced resistance to genotoxic agents, how does it confer this resistance? BCR/ABL stimulates numerous signaling molecules including Ras, PI-3k and STAT5, which are essential for leukemogenesis (de Groot et al., 1999; Goga et al., 1995; Nieborowska-Skorska et al., 1999; Puil et al., 1994; Sawyers et al., 1995; Sillaber et al., 2000; Skorski et al., 1994 Skorski et al., , 1995 Skorski et al., , 1997a Sonoyama et al., 2002) . In addition, activation of STAT5 and Ras but not PI-3k seems to play an important role in BCR/ABL-mediated resistance to apoptosis induced by DNA damage (Hoover et al., 2001; Sillaber et al., 2000; Slupianek et al., 2001; von Willebrand et al., 1998) . Recently, fibronectin-induced integrin signaling was implicated in the enhancement of BCR/ABL-mediated resistance to girradiation, and this effect was dependent on PI3k?Akt pathway (van der Kuip et al., 2001) . Thus, it seems that at least three major signaling pathways involving Ras, STAT5 and also PI-3k may be engaged in BCR/ABL-induced resistance to DNA damage.
What are the effector mechanisms activated downstream of BCR/ABL?STAT5, BCR/ABL?Ras, BCR/ABL?PI-3k and BCR/ABL?? (still not identified) signaling pathways which execute the appearance of a DNA damage-resistant phenotype? Assuming that drug metabolism and uptake/efflux are not important (see above), three other mechanisms could be envisaged (Figure 1 ). First, BCR/ABL-positive cells might repair DNA damage more rapidly; second, they might activate DNA damage-dependent cell cycle checkpoints more readily, allowing more time for DNA repair; and third, they might activate mechanisms that protect them from the pro-apoptotic signaling pathways that are normally activated by DNA lesions. Let us consider each of these possibilities in turn.
Enhanced repair of DNA lesions
Recent advances in molecular biology, biochemistry and crystallography have contributed greatly to a better understanding of drug-DNA interactions and the mechanisms that lead to repair of DNA lesions or to apoptosis. This is not an easy task because various DNA lesions induced by different genotoxic therapies require different mechanisms of DNA repair (Coultas and Strasser, 2000; Modesti and Kanaar, 2001; Norbury and Hickson, 2001 ). The precise type of DNA damage depends on the genotoxic agent used, and each type of damage represents a unique challenge for the cell (Figure 2 ). Damaged bases, mismatches and adducts are not usually lethal, unless their number reaches a certain threshold, but if unrepaired or misrepaired, they cause mutations in the genome (Hoeijmakers, 2001 ). By contrast, even small numbers of double-strand breaks (DSBs) can be lethal if unrepaired; and if not repaired correctly they can induce chromosomal aberrations (Khanna and Jackson, 2001 ). Human cells may use at least seven different repair mechanisms to deal with DNA lesions that represent a 'clear and present danger' to survival and genomic integrity (Table 1) . These mechanisms -direct reversion, base-excision repair (BER), nucleotide-excision repair (NER), mismatch repair (MMR), homologous recombination repair (HRR), non-homologous endjoining (NHEJ) and single-strand annealing (SSA) -perform unique and/or partially overlapping functions. The DNA lesions sustained, and the mechanisms used to repair them, can depend on the tumor's origin.
Although the level of DNA damage in BCR/ABLtransformed cells may be higher than in nontransformed cells, the former cells can repair most of the lesions faster (Slupianek et al., 2002) . This facilitated repair is dependent on BCR/ABL catalytic activity, so it seems reasonable to hypothesize that BCR/ABL can accelerate DNA-damage repair. Which DNA repair pathways are modulated by BCR/ABL to contribute to DNA damage resistance? Mutagenesis assay demonstrated that cells expressing a deletion mutant of BCR/ABL that lacked the SH2 and SH3 domains of ABL (BCR/ABLDD) were sensitive to cisplatin and mitomycin C, whereas cells expressing full-length BCR/ABL were resistant to these drugs. The SH2 and SH3 domains of BCR/ABL are required to activate the transcriptional activator STAT5, and drug resistance could be reinstated in BCR/ABLDDpositive cells by expressing a dominant-active mutant of STAT5B (STAT5B-DAM) (Slupianek et al., 2001) . So, which of STAT5B's many target genes is/are responsible for drug resistance (Figure 3) ? Expression of the DNA repair gene RAD51 was upregulated in cells expressing either BCR/ABL or the combination of BCR/ABLDD and STAT5B-DAM, but not in the parental cell line or in cells expressing BCR/ABLDD alone (Slupianek et al., 2001) . STAT5 could drive transcription of a luciferase reporter gene fused to RAD51's promoter in cells expressing BCR/ABL, but not in cells expressing BCR/ABLDD. In addition RAD51 is a substrate of the apoptotic protease caspase 3, which is inhibited by BCR/ABL. RAD51 overexpression is sufficient to cause drug resistance because overexpression of RAD51 in BCR/ABLDD-expressing cells restored most of their ability to resist cisplatin and mitomycin C treatment, whereas expression of a RAD51 antisense sequence in BCR/ABL-expressing cells sensitized them to the drugs. Increasing RAD51 levels however, is not the only way in which BCR/ABL bolsters DNA repair: co-immunoprecipitations revealed that both c-ABL and BCR/ABL interact with RAD51. Phosphorylation of RAD51 was increased by cisplatin or mitomycin C in the parental cell line, which expresses c-ABL. By contrast, RAD51 was constitutively phosphorylated in cells expressing BCR/ABL. RAD51 has previously been reported to be phosphorylated by c-ABL on two tyrosine (Y) residues -Y54 and Y315. Tyrosine-to-phenylalanine (F) mutations of If the damage is limited to a single base, a 'short patch' is created: an endonuclease, APE-1, then generates a single nucleotide gap at the abasic site. DNA polb fills the gap, which is ligated by the XRCC1-DNA ligase 3 complex. If the damage is more extensive (2 -10 bases) a 'long patch' is created: the abasic site recruits the proliferating cell nuclear antigen (PCNA)-DNA pold/e complex for repair synthesis, followed by FEN1 endonuclease to remove the displaced DNA flap, and DNA ligase 1 for sealing (Hoeijmakers, 2001) . Nucleotide
This deals with a wide range of helix-distorting lesions. The damage recruits the XPA-RPA-XPC-TFIIH complex to form excision a pre-incision complex. After XPB and XPD have unwound about 20 bases around the lesion, the XPG and ERCC1-XPF repair (NER) endonucleases make 3' and 5' incisions, respectively. The excised fragment is removed and the gap is filled by PCNA-DNA pold/e and ligation (Hoeijmakers, 2001) . Mismatch
This repair mispaired/modified bases and insertion/deletion loops. MSH2-MSH6 binds to mismatches and single-base repair (MMR) loops, whereas MSH2-MSH3 focuses on insertion/deletion loops. These protein-DNA complexes attract MLH1-PMS2 or MLH1-PMS1 heterodimers followed by exonucleases, which excise the new strand past the mismatch/loop. Resynthesis steps involve PCNA, RFC, RPA and DNA pold/e (Fishel, 1999; Hoeijmakers, 2001; Kolodner and Marsischky, 1999) . Homologous
This repairs DSBs preferentially in late S and G2 phases of the cell cycle. DSB ends are resected by the recombination RAD50-MRE11-NBS1 complex to create single-stranded DNA tails. RAD51 paralogues, in collaboration with RPA, repair (HRR) RAD52 and RAD54, promote the invasion of the single stranded DNA to the intact sister chromatid to find a matching sequence, which is used as a template to heal the broken ends by DNA synthesis. Finally, the junctions between the homologous chromosomes (Holliday junctions) are untangled by resolvases (Hoeijmakers, 2001; Khanna and Jackson, 2001; Norbury and Hickson, 2001 ). Non-homologous This repairs double-strand breaks primarily in G1 phase. The ends of the breaks are not modified or are processed by end joining the RAD50-MRE11-NBS1 complex and/or DNA polymerases, and are then simply linked together, without any template, (NHEJ) using the end-binding KU70-KU80 complex and DNA-dependent protein kinase, followed by ligation by the XRCC4 ligase (Hoeijmakers, 2001; Khanna and Jackson, 2001 ).
Single-strand
This repairs DSBs using homology between the ends of the joined sequence. In contrast to HRR, the homology is found annealing not by invasion of the sister chromatid, but by the RAD50-MRE11-NBS1-mediated resection of the broken ends to (SSA) create single-stranded DNA tails. When this resection reveals complementary sequences, the two DNA tails are annealed before being ligated by ligase 4. The overhanging tails are then trimmed by the XPF-ERCC1 endonuclease (Khanna and Jackson, 2001; Norbury and Hickson, 2001) . : by increasing its expression, decreasing its degradation and activating it through post-translational modification. Next, the association between drug resistance mediated by the BCR/ABL?STAT5 ?RAD51 pathway and HRR was examined in cells containing heteroallelic non-functional fragments of the GFP protein, which could be rescued by HRR after inflicting DSB in one of the GFP fragment. Expression of BCR/ABL, but not of BCR/ABL kinase-deficient mutant, increased the efficiency of HRR, which was reverted by downregulation of RAD51 (Slupianek et al., 2001) . Altogether, it seems that BCR/ABL?STA-T5?RAD51 pathway stimulates repair of DNA lesions by the HRR mechanism, which contributes to the resistance of leukemia cells to drug-induced DNA damage. RAD51 protein is of particular interest in the study of cellular response to DNA damage because of its structural and functional similarity to the E. coli RecA protein (Shinohara and Ogawa, 1995) . RecA is known to play a central role in the prokaryotic response to DNA damage (Kowalczykowski et al., 1994) . The functional form of RecA and RAD51 is a multimeric helical nucleoprotein filament (Campbell and Davis, 1999) . RecA filaments are rapidly assembled on the single-stranded DNA segments that form after various types of DNA damage. Both RecA and RAD51 promote homology-dependent repair of DNA double strand breaks (DSBs) (Kowalczykowski et al., 1994; Shinohara and Ogawa, 1995) . Homology-dependent DSB repair is an accurate process that usually repairs DSBs without generating insertions, deletions, or other chromosomal rearrangements. This accuracy results from the use of an undamaged copy of broken DNA as a template for the repair process. The recruitment of an undamaged copy of the DNA requires strand exchange activity. Like RecA human RAD51 promotes the ATP-dependent DNA strand exchange in vitro, indicating that the role of RAD51 in recombinatorial DSB repair is likely to be conserved in mammals (Baumann et al., 1996; Namsaraev and Berg, 1997; Shinohara et al., 1992) .
Elevated levels of RAD51 proteins have been observed in many tumors (Raderschall et al., 2002) and, in general, positively correlated with resistance to genotoxic treatment (Collis et al., 2001; Vispe et al., 1998) . It was reported that even 2 -3-fold increase of RAD51 level increased homologous recombination by 20-fold and induced resistance to ionizing radiation (Vispe et al., 1998) . On the other hand, downregulation of RAD51 can be lethal, because RAD51 is necessary for procession of spontaneously occurring homologous recombination events involving sister chromatids formed after the S phase (Sonoda et al., 1998 (Sonoda et al., , 1999 . Altogether, it seems that a 'basal' level of RAD51 is required for cell proliferation and chromosomal integrity, but constitutive elevation and tyrosine phosphorylation of RAD51 in BCR/ABL-induced tumor cells may lead to acquired drug resistance.
Several mitotic paralogues of the RAD51 protein have been identified in mammals including highly conserved RAD51 (Shinohara et al., 1993) , RAD51B (Albala et al., 1997) , RAD51C (Dosanjh et al., 1998) , RAD51D (Pittman et al., 1998) , XRCC2 Thacker et al., 1995) and XRCC3 (Tebbs et al., 1995) . RAD51 paralogues form at least two different complexes involving RAD51B+RAD51C+RAD51D+XRCC2 (BCDX2) and RAD51C+XRCC3, which can interact with RAD51 to promote strand invasion and/or pairing during homologous recombination (Masson et al., 2001) . BCR/ABL can modulate the expression levels of RAD51 paralogues (Slupianek et al., 2001) , thus it may further modify the efficiency of pairing ( Figure 5 ).
The importance of HRR in resistance to DNA damage in BCR/ABL-positive cells has been strength- ened by the observation that another prime mechanism of DSB repair, NHEJ, seems to be down-modulated by BCR/ABL-mediated, proteasome-dependent degradation of DNA-PK cs , the essential element in NHEJ (Deutsch et al., 2001) . Because HRR and NHEJ compete for the repair of a DSB (Pierce et al., 2001a) , HRR might become a major mechanism of DSBs repair in cells exhibiting low activity of NHEJ. However, recent studies showed that NHEJ could work also without DNA-PK cs (DiBiase et al., 2000; Smith and Jackson, 1999) . Using comet assay we observed that DNA damage was repaired more efficiently in BCR/ABL-positive cells in comparison to control cells Slupianek et al., 2002) . Since most of the fast-track reparation of DNA damage observed in comet assay does not depend on HRR mechanisms but rather on NHEJ (DiBiase et al., 2000; Wang et al., 2001) , it suggests that BCR/ABL may in fact stimulate the NHEJ mechanism, which does not depend on DNA-PK cs .
At this time it is not known if and how BCR/ABL affects the reparation of small DNA lesions such as mismatches, base damage or adducts. BCR/ABL potentially interacts with the xeroderma pigmentosum group B protein (XPB), a vital subunit of the basal transcription factor TFIIH complex working in NER . This interaction may be associated with modification of XPB's ability to interact with other members of the TFIIH complex (Maru et al., 2001) . However, the functional outcome of this effect is not clear, because NER appears to be only modestly affected by BCR/ABL (Maru et al., 2001) .
Checkpoint activation
Global DNA repair capability can be affected not only by the efficiency of repair mechanisms, but also by the time allowed for repair. DNA damage checkpoints ( Table 2 ) control both the length of the cell cycle phase and the activation of DNA repair pathways and movement of DNA repair proteins to the sites of DNA damage, thus helping to integrate DNA repair with cell cycle progression (Dasika et al., 1999a; Zhou and Elledge, 2000) . Disassociation of the checkpoints and DNA repair mechanisms can lead to apoptosis or genomic instability (Bracey et al., 1997; Chan et al., 1999; Elledge, 1996; Shapiro and Harper, 1999) .
Reports from several laboratories, including ours, have shown that BCR/ABL-positive cells display pronounced G2/M delay in response to various chemotherapeutics, including cisplatin, mitomycin C, etoposide and daunorubicin, which seems to be an essential component in the resistance to DNA damage Figure 5 BCR/ABL modulates RAD51 paralogues. RAD51 paralogues form at least two different complexes involving RAD51B +RAD51C+RAD51D+XRCC2 (BCDX2) and RAD51C+XRCC3, which can interact with RAD51 to promote strand invasion and/or pairing during homologous recombination. BCR/ABL can upregulate and phosphorylate RAD51. In addition, BCR/ABL may differentially regulate the expression of various RAD51 paralogues Nishii et al., 1996) . However, G2/M checkpoint activation by BCR/ABL in response to irradiation remains controversial. Although results from p210BCR/ABL-positive human and mouse cell lines implicated G2/M delay in their resistance to irradiation Nishii et al., 1996) , these from p190BCR/ABL-transformed mouse primary cells failed to demonstrate the G2/M delay and resistance . This discrepancy may be due to the differences in leukemia phenotype and/or signaling pathways induced by p210BCR/ABL and p190BCR/ ABL kinases (Ilaria and van Etten, 1996; Quackenbush et al., 2000; Voncken et al., 1995) , or in the experimental conditions (only a sub-population of p190BCR/ABL cells have been analysed ).
G2/M phase is generally controlled by two checkpoints: at the G2?M transition (G2 checkpoint) and at the metaphase?anaphase transition (M checkpoint) (Dasika et al., 1999b; Shah and Cleveland, 2000) . G2 checkpoint depends on the mechanisms regulating cdc2-cyclin B1 complex such as: (1) ATM?Chk1? serine phosphorylation of cdc25C phosphatase driving it outside the nucleus and preventing activation of cdc2-cyclin B1, and (2) p53?p21 and 14-3-3s resulting in inactivation and sequestration of cdc2-cyclin B1 complex in the cytoplasm (Chan et al., 1999) . M checkpoint is controlled by the mitotic spindle assembly mechanisms (Shah and Cleveland, 2000) . Genetic and biochemical evidence showed that G2 and M checkpoints could be activated by DNA lesions to prolong G2/M phase and reduce the cytotoxicity of DNA damage (Chan et al., 2000; Johnson et al., 1999; Li and Cai, 1997; . The mechanisms of G2/M delay in BCR/ABL-positive cells have not been characterized, but regulation of cdc2-cyclin B1 could be involved (Nishii et al., 1996) . Although there is no direct evidence that BCR/ABL can affect the M checkpoint, our unpublished results suggest that CML cells contain elevated levels of MAD2 and BUB1, which inhibit the anaphase-promoting complex and cause mitotic spindle arrest (Shah and Cleveland, 2000) . Thus, it seems reasonable to postulate that both G2 and M checkpoints may contribute to G2/M delay in BCR/ABL-positive cells treated with DNA damaging agents. We speculate that by prolongation of the G2/M phase, BCR/ABL creates a 'window of opportunity' for the HRR mechanisms (which operate in late S and G2 phase) to repair more DSBs and allow tumor cells to escape from the apoptotic pathway. This hypothesis is supported by the observation that simultaneous overexpression of RAD51 and induction of a G2/M delay in untransformed cells causes significant resistance to DNA damage (Slupianek et al., 2002) .
Regulation of Bcl-2 family
It is believed that DNA damage simultaneously triggers the repair mechanisms and the apoptotic pathways (Li, 1999) . So, even if DNA repair mechanisms are enhanced, tumor cells can still be exposed to the strong pro-apoptotic signals. In response to this challenge, BCR/ABL-positive cells have developed the third (in addition to HRR and G2/ M delay) line of defense against genotoxic treatment: modulation of Bcl-2 family members (Table 3) .
The Bcl-2 family plays an important role in response to genotoxic treatment (Makin and Hickman, 2000) . These proteins seem to function as integrators of 
G1/S
This checkpoint ensures that damaged DNA is not replicated. DNA damage activates protein kinases including ATM, ATR and c-ABL. These lead to phosphorylation of p53 and p73, resulting in upregulation of the expression of the cyclin-dependent kinase inhibitor WAF1 (also known as p21). WAF1 can bind several cyclin-CDK complexes and might mediate the G1/S checkpoint. Genotoxic stress also induces the rapid ubiquitylation -and degradation of Cdc25A, the protein phosphatase that dephosphorylates Cdk2. Dephosphorylated Cdk2 activates cyclin E-Cdk2 and promotes the G1/S progression, so this degradation of Cdc25A, which is dependent on the activation of another kinase, Chk1, provides another means of halting the cell cycle (Dasika et al., 1999a; Mailand et al., 2000; Zhou and Elledge, 2000) . S This checkpoint prevents replication if DNA damage was not repaired in G1 phase or did not occur until in early S phase. The exact mechanism of this checkpoint is poorly understood. It seems that DNA damage-dependent activation of ATM is responsible for activation of Chk2, which phosphorylates Cdc25A on Ser123 and promotes its ubiquitylation (Falck et al., 2001 ).
G2
This checkpoint presumably allows for repair of DNA that was damaged in late S phase or G2 phase, and to prevent damaged DNA being segregated into daughter cells. It depends on the inhibition of cdc2 kinase activity, which is activated by phosphorylation at Thr161 by Cdk-activating kinase (CAK) and dephosphorylation on Tyr15 and Thr14 by Cdc25C phosphatase. DNA-damage-dependent stimulation of ATM/ATR activates Chk1 and/or Chk2, which phosphorylate Cdc25C on Ser216. This creates a binding site for the 14-3-3 proteins, and results in nuclear export of Cdc25C and its retention in the cytoplasm. Nuclear cdc2 remains phosphorylated in the absence of Cdc25C and cells are arrested in the G2 phase. ATM/ATR also phosphorylates and stabilizes p53, causing up-regulation of 14-3-3, GADD45 and p21 proteins, thus escalating the cytoplasmic retention of Cdc25C and inhibition of the cdc2-cyclin B complex. In addition, p53 represses the transcription of cdc2 and cyclin B (Chan et al., 1999 (Chan et al., , 2000 Dasika et al., 1999a; Taylor and Stark, 2001; Zhou and Elledge, 2000) . M This checkpoint controls mitotic spindle and metaphase-anaphase transition. Mitotic entry is associated with chromosome condensation, formation of the mitotic spindle and activation of the anaphase-promoting complex (APC) responsible for initiation of the physical separation of sister chromatids during anaphase. If chromosomal errors occur mitotic spindle may not form and/or APC is not activated. Cells arrested in M phase can decondense their chromosomes and return to G2 phase before re-entering M phase, perhaps allowing for better access of DNA repair machinery to the lesions (Shah and Cleveland, 2000) .
damage signals, and might be the final decision point as to whether a cell lives or dies. BCR/ABL can modulate the expression as well as post-translational modification of Bcl-2 family members to provide protection from apoptosis. BCR/ABL affects antiapoptotic proteins such as Bcl-x L (Amarante- Mendes et al., 1998a; Horita et al., 2000) and Bcl-2 (Skorski et al., 1997a) , and the pro-apoptotic protein Bad (Neshat et al., 2000; Salomoni et al., 2000) . Some of the BCR/ ABL-dependent signaling pathways leading to the modulation of Bcl-2 proteins have been identified. For example, BCR/ABL can activate STAT5, which contributes to the overexpression of Bcl-x L (de Groot et al., 2000; Gesbert and Griffin, 2000) . In addition, a serine-threonine kinase Akt is activated by BCR/ABL (Skorski et al., 1997a) and may phosphorylate and inactivate Bad, which keeps it in complex with 14-3-3 proteins, away from mitochondria (Zha et al., 1996) . These events might prevent the release of cytochrome c from the mitochondria and activation of caspase-3 (Amarante- Mendes et al., 1998b; Dubrez et al., 1998) , thus contributing to the BCR/ABL-mediated resistance to genotoxic treatment.
HRR, G2/M delay and Bcl-x L work in concert to induce drug resistance in BCR/ABL-positive cells
Individually, elevated levels of RAD51 or Bcl-x L , or G2/M delay were responsible for induction of a modest drug resistance in normal hematopoietic cells (Slupianek et al., 2002) . Interestingly, combination of these three factors in non-transformed cells induced drug resistance of the magnitude similar to that observed in cells expressing BCR/ABL. In conclusion, DNA repair mechanisms, cell cycle checkpoint mechanisms and Bcl-2 family proteins can therefore work in concert to protect BCR/ABL-transformed cells from death induced by genotoxic stress (Slupianek et al., 2002) . A comprehensive model of drug resistance in BCR/ ABL-transformed cells is presented in Figure 6 .
BCR/ABL-family of oncogenic fusion tyrosine kinases protects from DNA damage-induced apoptosis
Chromosomal translocations are responsible for the appearance of oncogenes encoding fusion tyrosine kinases (FTKs) such as BCR/ABL, TEL/ABL, TEL/ JAK2, TEL/PDGFbR, TEL/TRKC(L) and NPM/ ALK, which induce various leukemias and lymphoma (Blume-Jensen and Hunter, 2001; Kolibaba and Druker, 1997) . These FTKs (BCR/ABL-family FTKs) share structural similarity, which include an aminoterminal oligomerization domain responsible for constitutive oligomerization and activation of the associated tyrosine kinase of the carboxy-terminal fusion partner. FTK-transformed cells displayed drug resistance against cytostatic drugs: cisplatin and mitomycin C (Slupianek et al., 2002) . These cells were not protected from drug-mediated DNA damage implicating activation of the mechanisms preventing DNA damageinduced apoptosis. Various FTKs, except TEL/ TRKC(L), can activate STAT5, which may be required to induce drug resistance (Hoover et al., 2001; Sillaber et al., 2000) . We show that STAT5 is essential for FTKs-dependent upregulation of RAD51, which plays a central role in HRR of DSBs (Slupianek et al., 2002) . Elevated levels of RAD51 contributed to the induction of drug resistance and facilitation of the HRR in FTKtransformed cells. In addition, expression of the antiapoptotic protein Bcl-x L was enhanced in cells transformed by the FTKs, which were able to activate STAT5. Moreover, cells transformed by all examined FTKs, displayed G2/M delay upon drug treatment. In conclusion, we postulate that RAD51-dependent facilitation of DSB repair, anti-apoptotic activity of Bcl-x L and delay in progression through the G2/M phase may eventually work in concert to induce drug resistance in leukemias and lymphomas expressing one of the members of BCR/ABL-family FTKs.
BCR/ABL-induced genomic instability
Clinical observations (Alimena et al., 1987; Kelman et al., 1989; Rowley and Testa, 1982) and experimental findings (Honda et al., 2000; Laneuville et al., 1992; have shown that BCR/ ABL can induce genomic instability, leading to chromosomal translocations, deletions, additional chromosomes, gene amplifications and mutations. How is this phenomenon linked with aberrations in pathways regulating DNA damage response in BCR/ ABL-positive leukemia cells? In normal cells, DNA repair mechanisms are tightly regulated and in balance with apoptotic pathways, so cells with an excess of Bcl-2 Bax An important site of activity of the Bcl-2 proteins is the mitochondrial membrane. Following a variety of death Bcl-x L Bak signals, members of pro-apoptotic Bcl-2 family members undergo certain modifications; for example, Bax Bcl-w Bok dimerizes, Bad is dephosphorylated and Bid is cleaved. These modifications allow the pro-apoptotic Bcl-2-family Mcl-1 Bcl-xS members to translocate to mitochondria and/or to heterodimerize with the anti-apoptotic members of the family. A1 Bad Homodimerization (e.g. Bax-Bax) or heterodimerization (e.g. Bcl-x L -Bad) is an essential step for regulation Bid of the release of cytochrome c from mitochondria. Cytosolic cytochrome c activates a proteolytic caspases Bik cascade that leads to apoptotic death (Antonsson and Martinou, 2000; Gross et al., 1999 ) Bim DNA damage and/or with irreparable lesions that pose a threat to genomic stability are eliminated. However, BCR/ABL-positive tumor cells seem to be better equipped to survive genotoxic damage. BCR/ABL modulates the sensitivity to DNA damage by facilitating repair of DNA lesions and inhibiting damageinduced apoptotic mechanisms, as discussed above. However, given that DNA repair may not be 100% accurate, might this accelerated repair actually contribute to genomic instability?
In general, two types of DNA damage can contribute to genomic instability: spontaneous damage that simply occurs as the result of the infidelity of replication and/or the accumulation of compounds such as ROS, and damage caused by external factors, such as genotoxic therapies. BCR/ABL enhances ROS formation, which probably comes from mitochondria and NADPH oxidase (Benhar et al., 2001; . It could be postulated that elevated levels of ROS in BCR/ABL-transformed cells may contribute to spontaneous damage and genomic instability (Aitken and Krausz, 2001 ). ROS interact with DNA to cause an oxidative damage, e.g. 8-hydroxy-2'-deoxyguanosine (8-oxoG) (Laval, 1996) . If unrepaired, these lesions can exert a number of deleterious effects including the induction of mutations such as: GC?AT transitions and GC?TA transversions (Wang et al., 1998) , and DSBs (Michel et al., 2001 ). In addition, BCR/ABL-transformed cells, in comparison to normal cells, may accumulate more DNA damage after genotoxic treatment (Slupianek et al., 2002) , further increasing their chances to harbor genetic errors. Moreover, mechanisms necessary for the repair of DNA lesions might be compromised by BCR/ ABL as described above (Deutsch et al., 2001; Maru et al., 2001; Slupianek et al., 2001) . So, the probability of accumulating DNA errors seems to be much higher in BCR/ABL-positive cells compared with non-transformed cells, probably because more DNA damage occurs and the fidelity of repair mechanisms is compromised, which leads to misrepair.
Destabilized DNA repair mechanisms could play an important role in genomic instability. For example, HRR, NHEJ and MMR normally act to maintain genetic stability but, if they are deregulated, genomic instability and malignant transformation might occur (Flores-Rozas and Kolodner, 2000; Kolodner and Marsischky, 1999; Pierce et al., 2001b; Richardson and Jasin, 2000) . Because the human genome contains *500 000 members of the Alu family (*300 base-long repetitive sequences interspersed ubiquitously throughout the genome) (Rinehart et al., 1981) , increased levels of homologous/homeologous recombination events between such repeats might lead to increased genomic instability and contribute to malignant progression. Interestingly, there is a transient increase in the . Extensive DNA damage cannot be efficiently repaired and cell cycle checkpoints are not strong enough to allow more time for repair. As a result, unrepaired lesions trigger pronounced death-signaling pathways in the nucleus. Signals of this magnitude cannot be inhibited in the cytoplasm by the 'basal' activity of Bcl-2 family proteins, resulting in the release of cytochrome c from mitochondria, activation of caspase-3 and apoptosis. In contrast, cells transformed by BCR/ABL (red) sustain more DNA damage, but increase levels of global DNA repair, while the repair fidelity and ability to repair some lesions could be compromised. In addition, effective stimulation of cell cycle checkpoints (mainly G2/M checkpoint) provides extra time for repair. Overall, lethal damage is repaired efficiently and most apoptotic signaling from lesions that are unrepaired or misrepaired might be controlled by modulation of the Bcl-2 protein family. Therefore, release of cytochrome c from mitochondria and activation of caspase-3 is effectively decreased. In this way, BCR/ABL-positive cells can better survive genotoxic stress and accumulate DNA lesions, leading to genomic instability and malignant progression accessibility of Alu chromatin to enzymatic cleavage after stress, which might facilitate recombinational events between these sequences (Kim et al., 2001) . In fact, repetitive DNA elements are frequently precursors to chromosomal deletions (Gebow et al., 2000) . So, in addition to its role in drug resistance, the high activity of HRR observed in BCR/ABL-positive leukemias might be responsible for intra-chromosomal or interchromosomal deletions and chromosomal translocations that depend on recombination between regions of shared homology such as Alu sequences (Bishop and Schiestl, 2001 ). This hypothesis is supported by the recent finding that large submicroscopic deletions in regions with high overall density of Alu sequence repeats have been detected in BCR/ABL-positive leukemias (Kolomietz et al., 2001) .
HRR-dependent mechanisms can facilitate loss of heterozygosity (LOH) by gene conversion mechanisms . BCR/ABL cells should be predisposed to LOH, because they contain high levels of Bcl-x L (Amarante-Mendes et al., 1998a; Horita et al., 2000) , which promotes irradiation-induced mutagenesis by gene conversion (Cherbonnel-Lasserre et al., 1996; Wiese et al., 2002) . In support of this hypothesis BCR/ABL enhanced gene conversion-dependent repair of DSBs (Slupianek et al., 2001) . LOH is frequently observed in tumor development and progression, and can involve important cancer genes such as RB and TP53 (Cavenee et al., 1983; Ikawa et al., 1999) . Mutations of TP53 are often seen during malignant progression of many tumors, including BCR/ABLpositive leukemias (Beck et al., 2000; Guinn et al., 1995; Nakai et al., 1992; Stuppia et al., 1997) . Loss-offunction of wild-type TP53 can result in loss of the G1/ S cell cycle checkpoint ) and an increase of HRR (Gebow et al., 2000) . Facilitation of genetic exchanges (HRR) in the absence of the G1/S checkpoint might be due to generation of recombinogenic structures during the replication of DNA lesions or due to the uncontrolled entry of cells that already contain recombination intermediates into the S phase (Willers et al., 2000) . As p53 seems to interact with RAD51 (Sturzbecher et al., 1996) , the absence of p53 might enhance RAD51-mediated DNA strand pairing activity and HRR. In support of this hypothesis, intrachromosomal deletions of repetitive elements such as Alu sequences occur with higher frequency after loss-of-function of p53 and/or ATM, which is upstream of p53 (Gebow et al., 2000; Meyn, 1993) . These deletions might cause further genomic instability, for example Alu-mediated HRR has been reported to cause rearrangements in BRCA1, resulting in its loss of activity (Rohlfs et al., 2000) . Inactivation of BRCA1 has been implicated in chromosomal instability (Moynahan et al., 1999) .
HRR events might also promote small mutations or insertions. HRR has been reported to be involved in somatic hypermutation of immunoglobulin variable regions by recruiting a low-fidelity DNA polymerase (Papavasiliou and Schatz, 2000) . Interestingly, BCR/ ABL enhances the expression and activity of polymerase b, the inaccurate polymerase (Canitrot et al., 1999) . Accordingly, BCR/ABL-expressing cells should accumulate HRR-related somatic mutations. In addition, HRR is a robust mechanism for expanding triplet repeats (Jakupciak and Wells, 2000) . Moreover, larger mutations (extra sequences) are introduced into many HRR sites, because numerous interchromosomal recombination events between homologous sequences are initiated as HRR but can be completed by the less accurate NHEJ pathway (Richardson and Jasin, 2000) .
RAD51 protein needs support from its paralogues ( Figure 5 ) in order to function properly (Baumann and West, 1998) . As RAD51's paralogues, like RAD51 itself, can be deregulated by BCR/ABL (Slupianek et al., 2001) , it seems reasonable to speculate that under such conditions the efficiency and/or fidelity of HRR might be compromised. Accordingly, even if elevated RAD51 can induce more 'pairing' events, they might not be appropriately initiated or processed. This mechanism may contribute to genomic instability in BCR/ABL-transformed cells. Moreover, under certain conditions, HRR can permit exchange between DNA strands containing short non-homologous sequences (Bucka and Stasiak, 2001) or mismatches (Elliott and Jasin, 2001) . In this way, changes in the cellular levels or the activity of RAD51 and other proteins involved in DNA repair might not only cause drug resistance, but also promote genomic instability.
Direct evidence that overexpression of RAD51 can induce chromosomal instability has been obtained by showing that elevated RAD51 protein can stimulate intra-and inter-chromosomal deletions by promoting non-homologous recombination (Arnaudeau et al., 2001) . In addition, overexpression of RAD51 can cause chromosomal aberrations in mammalian cells (Dr C Richardson, Columbia University, New York, NY; personal communication). Finally, studies of yeast artificial chromosomes (YACs) in Saccharomyces cerevisiae showed that RAD51 -RAD52 pathway(s) are involved in the instability of YACs containing tandem repeat loci, presumably by promoting HRRdependent deletion of one of the repeats (Kohno et al., 1997) . By contrast, YACs are stabilized in a rad51/rad52 double mutant strain. In sum, dysregulation of HRR, which normally represents a faithful mechanism of DNA repair, can contribute to genomic instability and carcinogenesis (Bishop and Schiestl, 2001) .
In BCR/ABL-expressing cells, downregulation of the catalytic subunit of DNA-dependent protein kinase (DNA-PK cs ) (Deutsch et al., 2001) , an enzyme involved in NHEJ, might exert an inhibitory effect on NHEJ, which normally has an important function in maintaining genomic integrity Richardson and Jasin, 2000) . Accordingly, downmodulation of NHEJ might contribute to the occurrence of chromosomal aberrations. Moreover, modest inhibition of NER by BCR/ABL may create problems in repairing various helix-distorting lesions, thereby allowing mutations to accumulate (Maru et al., 2001 ).
Strategies for overcoming DNA damage resistance
Combining different cytotoxic drugs and irradiation is a widely and successfully used clinical strategy in oncology that increases the response rate and duration of individual drugs but unfortunately, as we have discussed, BCR/ABL-expressing tumor cells may be inherently resistant to this approach. But we have also mentioned that this drug resistance seems to depend on the BCR/ABL catalytic activity , so inhibiting BCR/ABL kinase in conjunction with chemo/radiotherapeutics should, in theory increase the efficiency of genotoxic treatments (Fang et al., 2000; Skorski et al., 1993; Thiesing et al., 2000) . In addition, expression of the cytokine receptors that are normally required for survival of hematopoietic cells may be downregulated by BCR/ABL (Donato et al., 2001) . Activation of these receptors by specific ligands can protect cells to some degree from DNA damageinduced apoptosis (Collins et al., 1992) . Therefore, inhibition of BCR/ABL kinase should create a brief window of opportunity, before cytokine receptors expression is back to normal levels, when leukemia cells might be even more sensitive to cytotoxic drugs than normal cells. During this time inhibitor-treated BCR/ABL-positive cells lose the protection afforded by BCR/ABL and also do not exhibit that 'basal' protection induced by cytokine-receptor interaction, while normal cells remain at least partially protected by cytokine-receptor -dependent signaling.
Recent clinical trials with STI571 (Gleevec, imatinib mesylate), a selective inhibitor of the BCR/ABL kinase, have shown that this compound has significant antileukemia activity in all phases of CML as well as Ph 1 -positive ALL (Druker et al., 2001a,b) . Combination of STI571 with commonly used anti-leukemic agents was shown to exert increased cytotoxic effect against BCR/ ABL-positive cell lines and CML cells as compared with STI571 alone (Fang et al., 2000; Kano et al., 2001; Slupianek et al., 2002; Thiesing et al., 2000; Topaly et al., 2001) . Our previous findings that downregulation of BCR/ABL by the antisense oligodeoxynucleotides combined with cyclophosphamide exerted synergistic anti-leukemic effect, support this observation (Skorski et al., 1993 (Skorski et al., , 1997b . Thus, combinations of BCR/ABL inhibitors with antileukemic drugs may have improved efficacy against Ph 1 -positive leukemias. These reports are in agreement with our finding that RAD51 is downregulated in STI571-treated leukemia cells (Slupianek et al., 2002) . However this effect may disappear as leukemia progresses toward more malignant stage, which is usually accompanied by secondary genetic changes often making cells independent of BCR/ABL, e.g., activation of STAT5 (Klucher et al., 1998) . Thus, RAD51 may become upregulated independently of BCR/ABL, promoting resistance to DNA damage even if BCR/ABL kinase is inhibited. There are approaches focusing on overcoming/ avoiding the BCR/ABL-mediated protection of tumor cells from apoptosis induced by genotoxic treatment. For example, amifostine, a pro-drug used to protect normal cells against chemotherapeutic drugs (Grdina et al., 2000) , dramatically increased idarubicin-induced DNA damage in cells expressing TEL/ABL, and at the same time protected normal non-transformed cells . This combination may also exert a beneficial effect against BCR/ABL-positive cells. In addition, BCR/ABL-positive leukemia cells are resistant to apoptosis induced in the absence of growth factors and by DNA damage, but remain sensitive to apoptosis triggered by cytotoxic T lymphocytes (CTL) and natural killer or lymphokine-activated killer cells (Fuchs et al., 1995; Roger et al., 1996) . The leukemiareactive CTL cell lines generated from an HLAidentical donor induced complete remission of accelerated phase chronic myelogenous leukemia (Falkenburg et al., 1999) .
In summary, combination of different approaches including molecular targeting of BCR/ABL, chemo/ radiotherapy and/or immunotherapy may be highly effective . In addition, multiple mechanisms involved in drug resistance (HRR, G2/M delay and Bcl-2 family) can be simultaneously targeted, e.g. RAD51 antisense+ caffeine (to inhibit G2/M)+Bcl-x L antisense, along with chemo/radiotherapy.
